Anavex Life Sciences Corp (AVXL)

[falconer66a]

Very Different MOAs

If Leqembi can't treat even the symptoms of the APOE4++ subset, isn't it at least as likely blarcamesine can't treat its cause?

Well, if the mechanisms of action (MOAs) of both drugs were the same, or even similar, that conjecture might follow. But unlike Leqembi blarcamesine does not directly target amyloid plaques by immunological processes. It’s MOA is very different; modulating and promoting homeostatic (cell-keeping) processes.